Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Overweight on GitLab, Lowers Price Target to $60

Keybanc Maintains Overweight on GitLab, Lowers Price Target to $60

Keybanc analyst Michael Turits maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $63 to $60.

byBenzinga Newsdesk

December 6, 2022

1 minute read

Keybanc analyst Michael Turits maintains GitLab (NASDAQ:GTLB) with a Overweight and lowers the price target from $63 to $60.

Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $63

By Benzinga Newsdesk

November 23, 10:01 AM

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $83 to $63.

CRSP

‘Powell F’ed Everyone’: ‘Rich Dad Poor Dad’ Author Lashes Out At Powell, Yellen And Biden

By Chris Katje

March 23, 7:09 PM

One of the most well-known voices in the financial industry is speaking out against some of the top decision-makers after recent events.

BTC

Analyst Ratings

The Analyst Landscape: 3 Takes On Choice Hotels Intl

By Benzinga Insights

January 22, 2:01 PM

In the preceding three months, 3 analysts have released ratings for Choice Hotels Intl (NYSE:CHH), presenting a wide…

CHH

Analyst Ratings

Where Apellis Pharmaceuticals Stands With Analysts

By Benzinga Insights

August 24, 9:01 AM

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

APLS

Keybanc Maintains Overweight on GitLab, Lowers Price Target to $60

Related Posts

Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $63

‘Powell F’ed Everyone’: ‘Rich Dad Poor Dad’ Author Lashes Out At Powell, Yellen And Biden

The Analyst Landscape: 3 Takes On Choice Hotels Intl

Where Apellis Pharmaceuticals Stands With Analysts